Claims for Patent: 12,667,576

« Back to Dashboard

Summary for Patent: 12,667,576

Title:	Methods of treating and/or preventing actinic keratosis
Abstract:	The application pertains to methods of treating and/or preventing actinic keratosis, comprising administering a therapeutically effective amount of KX-01, to a subject in need thereof.
Inventor(s):	Min-Fun Rudolf KWAN, Johnson Yiu-Nam Lau, E. Douglas KRAMER, David Lawrence CUTLER, Jane FANG
Assignee:	ATNX SPV LLC
Application Number:	US17/963,502
Patent Claims:	1. A method of treating actinic keratosis comprising topically administering to a subject in need thereof a therapeutically effective amount of a compound of the following structure: to an affected area of the subject, wherein the therapeutically effective amount is 0.5 mg to 4 mg in a daily single dose unit and wherein the affected area is 0.1 cm2 to 100 cm2. 2. The method of claim 1, wherein the therapeutically effective amount is 0.5 mg to 3 mg. 3. The method of claim 1, wherein the therapeutically effective amount is 1 mg to 2.5 mg. 4. The method of claim 1, wherein the therapeutically effective amount is 1.3 mg to 2.5 mg. 5. The method of claim 1, wherein the therapeutically effective amount is 2.5 mg. 6. The method of claim 1, wherein the therapeutically effective amount is 1 mg to 4 mg. 7. The method of claim 1, wherein the therapeutically effective amount is 3 mg to 4 mg. 8. The method of claim 1, wherein the therapeutically effective amount is 3 mg. 9. The method of claim 1, wherein the affected area is 1 cm2 to 100 cm2. 10. The method of claim 1, wherein the affected area is 5 cm2 to 100 cm2. 11. The method of claim 1, wherein the affected area is 10 cm2 to 100 cm2. 12. The method of claim 1, wherein the affected area is 100 cm2. 13. The method of claim 7, wherein the affected area is 1 cm2 to 100 cm2. 14. The method of claim 7, wherein the affected area is 5 cm2 to 100 cm2. 15. The method of claim 7, wherein the affected area is 10 cm2 to 100 cm2. 16. The method of claim 7, wherein the affected area is 25 cm2 to 100 cm2. 17. The method of claim 7, wherein the affected area is 100 cm2. 18. The method of claim 1, wherein the affected area is 0.1 cm2 to 25 cm2. 19. The method of claim 1, wherein the affected area is 1 cm2 to 25 cm2. 20. The method of claim 1, wherein the affected area is 5 cm2 to 25 cm2. 21. The method of claim 1, wherein the affected area is 10 cm2 to 25 cm2. 22. The method of claim 1, wherein the affected area is 25 cm2. 23. The method of claim 5, wherein the affected area is 1 cm2 to 25 cm2. 24. The method of claim 5, wherein the affected area is 5 cm2 to 25 cm2. 25. The method of claim 5, wherein the affected area is 10 cm2 to 25 cm2. 26. The method of claim 5, wherein the affected area is 25 cm2. 27. The method of claim 1, wherein the therapeutically effective amount is 0.035 mg/cm2. 28. The method of claim 1, wherein the therapeutically effective amount is 0.1 mg/cm2. 29. The method of claim 1, wherein the compound is administered once a day. 30. The method of claim 5, wherein the compound is administered once a day. 31. The method of claim 7, wherein the compound is administered once a day. 32. The method of claim 17, wherein the compound is administered once a day. 33. The method of claim 26, wherein the compound is administered once a day. 34. The method of claim 27, wherein the compound is administered once a day. 35. The method of claim 28, wherein the compound is administered once a day. 36. The method of claim 1, wherein the compound is administered once a day for 5 consecutive days. 37. The method of claim 5, wherein the compound is administered once a day for 5 consecutive days. 38. The method of claim 7, wherein the compound is administered once a day for 5 consecutive days. 39. A method of treating actinic keratosis comprising topically administering to a subject in need thereof a therapeutically effective amount of a compound of the following structure: to an affected area of the subject, wherein the therapeutically effective amount is 0.5 mg to 4 mg and wherein the affected area is 0.1 cm2 to 100 cm2, wherein the affected area is the face or scalp. 40. The method of claim 39, wherein the therapeutically effective amount is 3 mg to 4 mg, the affected area is 100 cm2, and the compound is administered once a day for 5 consecutive days. 41. The method of claim 39, wherein the therapeutically effective amount is 2.5 mg, the affected area is 25 cm2, the compound is administered once a day for 5 consecutive days. 42. The method of claim 39, wherein the therapeutically effective amount is 0.035 mg/cm2 and the compound is administered once a day for 5 consecutive days. 43. The method of claim 39, wherein the therapeutically effective amount is 0.1 mg/cm2 and the compound is administered once a day for 5 consecutive days. 44. The method of claim 1, wherein the therapeutically effective amount is 3 mg to 4 mg, the affected area is 100 cm2, and the compound is provided in a daily single-dose unit administered once a day for 5 consecutive days. 45. The method of claim 1, wherein the therapeutically effective amount is 2.5 mg, the affected area is 25 cm2, and the compound is provided in a daily single-dose unit administered once a day for 5 consecutive days. 46. The method of claim 1, wherein the therapeutically effective amount is 0.035 mg/cm2, and the compound is provided in a daily single-dose unit administered once a day for 5 consecutive days. 47. The method of claim 1, wherein the therapeutically effective amount is 0.1 mg/cm2, and the compound is provided in a daily single-dose unit administered once a day for 5 consecutive days. 48. The method of claim 1, wherein the therapeutically effective amount is 0.035 mg/cm2, the affected area is the face or scalp and the compound is provided in a daily single-dose unit administered once a day for 5 consecutive days. 49. The method of claim 1, wherein the therapeutically effective amount is 0.1 mg/cm2, the affected area is the face or scalp and the compound is provided in a daily single-dose unit administered once a day for 5 consecutive days. 50. The method of claim 1, wherein the compound is topically administered to an affected area on the face or scalp of a subject in need thereof, once a day for 5 consecutive days at a single-dose unit of 2.5 mg to 4 mg over an affected area of 1 cm2 to 100 cm2. 51. The method of claim 50, wherein the single-dose unit is 3 mg to 4 mg. 52. The method of claim 51, wherein the affected area is 1 cm2 to 25 cm2. 53. The method of claim 51, wherein the affected area is 25 cm2 to 100 cm2. 54. The method of claim 50, wherein the single-dose unit is 2.5 mg. 55. The method of claim 54, wherein the affected area is 1 cm2 to 25 cm2. 56. The method of claim 54, wherein the affected area is 25 cm2 to 100 cm2. 57. The method of claim 54, wherein the affected area is 100 cm2.